Last reviewed · How we verify

ABT-267 — Competitive Intelligence Brief

ABT-267 (ABT-267) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CCR2 antagonist. Area: Immunology / Inflammation.

phase 3 CCR2 antagonist CCR2 (C-C chemokine receptor type 2) Immunology / Inflammation Small molecule Live · refreshed every 30 min

Target snapshot

ABT-267 (ABT-267) — AbbVie (prior sponsor, Abbott). ABT-267 is a selective inhibitor of the chemokine receptor CCR2 that reduces monocyte recruitment to sites of inflammation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ABT-267 TARGET ABT-267 AbbVie (prior sponsor, Abbott) phase 3 CCR2 antagonist CCR2 (C-C chemokine receptor type 2)
SR34006 SR34006 Sanofi phase 3 CCR2 antagonist CCR2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CCR2 antagonist class)

  1. AbbVie · 1 drug in this class
  2. AbbVie (prior sponsor, Abbott) · 1 drug in this class
  3. Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABT-267 — Competitive Intelligence Brief. https://druglandscape.com/ci/abt-267. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: